A growing number of Indian startups are betting consumers will pay thousands—and in some cases lakhs of rupees—to find and fix health problems before they become illnesses. According to reports from Company Business News, the opportunity is being driven by rising spending on fitness and wellness, greater awareness of preventive health, and for some businesses, the growing popularity of GLP-1 weight-loss drugs. India's health and wellness market was valued at ₹164 billion in 2025 and is projected to reach ₹257 billion by 2034, growing at a compound annual rate of 5%, according to Imarc Group. Spending on fitness and wellness by Gen Z is projected to grow from ₹11 billion in 2024 to ₹40 billion by 2030, with 30% of the generation spending more than 20% of their income on fitness and sports.
Companies building businesses around extensive health screenings, biomarker tracking and therapies include Biopeak, Ultrahuman, MetaGo, Cent Health and Nura. According to reports from Company Business News, Biopeak started in 2024 and has raised almost ₹90 crore from Manipal Group, Claypond Capital, Rainmatter and NKSquared. The startup plans to open six to eight more centres across India by early next year, with current operations at two centres in Bengaluru. Ultrahuman launched its diagnostics and therapeutics centre in May 2025, leveraging its existing wearable business for customer conversion. The company's diagnostics-only plans start at ₹10,000, while its all-inclusive Black membership costs ₹10 lakh annually.
The companies are pitching intensive preventive healthcare combining blood, genetic, imaging and gut-microbiome tests with interventions such as hyperbaric chambers, cryotherapy, infrared saunas and IV drips. According to reports from Company Business News, Biopeak says more than 80% of its roughly 800 customers arrive with specific health problems to solve rather than seeking longevity treatments. The most common issues include oxidative stress, non-alcoholic fatty liver disease, allergy-related issues and osteopenia in women. Ultrahuman's clientele is split across everyday athletes, professional sportspersons and those optimising for longevity, with customers aged 30-55 seeking solutions for diabetes and lifestyle chronic conditions.
The businesses are at different stages of scale, with Nura completing over 82,000 screenings across 25+ parameters since launching in 2021, and Cent Health completing 7,000 scans since opening its first centre in March. According to reports from Company Business News, Biopeak's Indiranagar centre cost $1.5-2 million to build, reflecting the equipment and clinical infrastructure required for diagnostics and therapies. The company's prices range from ₹1,10,000 to ₹1,30,000 including year-long customized plans. MetaGo's six-month and 12-month GLP-1 programmes cost ₹20,000 and ₹24,000 respectively, excluding approximately ₹5,000 monthly for medication.
Despite high prices, scaling remains a significant challenge for these preventive health startups. According to reports from Company Business News, Ultrahuman expects its Indiranagar centre to turn profitable in less than a year, while Biopeak's co-founder Rishi Pardal acknowledges the question of whether their model can replicate across 100 centres. The key challenge lies in whether the current business model can be scaled effectively while maintaining quality and profitability. As reported by Fireside Ventures co-founder Kannan Sitaram, the focus should be on scalability rather than individual clinic success, asking whether the model can become replicable across larger operations.
